Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Items 801–900 of 1,001
Yu, F., & Qian, Z. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171104 · Cited by 20
Neurofibromatosis type 1: Its association with the Ras/MAPK pathway syndromes
Bennett, E., Thomas, N. S. T., & Upadhyaya, M. (2009) · Journal of Pediatric Neurology · doi:10.3233/jpn-2009-0276 · Cited by 19
Derer, S., Berger, S., Schlaeth, M., Schneider‐Merck, T., Klausz, K., Lohse, S., Overdijk, M. B., Dechant, M., Kellner, C., Nagelmeier, I., et al. (2012) · Neoplasia · doi:10.1593/neo.111636 · Cited by 25
Zeng, L., Li, J., Li, J., Zhang, Q., Qian, C., Wu, W., Zhong, L., Liang, J., Chen, Y., & Huang, K. (2014) · Pancreas · doi:10.1097/mpa.0000000000000241 · Cited by 19
Wnt4 inhibits cell motility induced by oncogenic Ras
Menna, M. D., D'Amato, V., Ferraro, A., Fusco, A., Lauro, R. D., Garbi, C., & Vita, G. D. (2012) · Oncogene · doi:10.1038/onc.2012.419 · Cited by 19
Oncogenic Ras influences the expression of multiple lncRNAs
Kotake, Y., Naemura, M., Kitagawa, K., Niida, H., Tsunoda, T., Shirasawa, S., & Kitagawa, M. (2014) · Cytotechnology · doi:10.1007/s10616-014-9834-9 · Cited by 20
Binding properties and biological characterization of new sugar-derived Ras ligands
Sacco, E., Abraham, S. J., Palmioli, A., Damore, G., Bargna, A., Mazzoleni, E., Gaponenko, V., Vanoni, M., & Peri, F. (2011) · MedChemComm · doi:10.1039/c0md00264j · Cited by 20
The G2 p38-Mediated Stress-Activated Checkpoint Pathway Becomes Attenuated in Transformed Cells
Mikhailov, A. V., Patel, D., McCance, D. J., & Rieder, C. L. (2007) · Current Biology · doi:10.1016/j.cub.2007.11.028 · Cited by 19
RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma
Jiang, C., Song, T., Li, J., Fan, A., Gong, X., Lu, Y., Zhang, C., Chen, L., Liu, Y., He, H., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9763-z · Cited by 19
Li, Z., & Buck, M. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00690 · Cited by 20
Zhu, B., Khozoie, C., Bility, M. T., Ferry, C. H., Blazanin, N., Glick, A. B., Gonzalez, F. J., & Peters, J. M. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00092-12 · Cited by 19
Yoshikawa, K., Tanabe, E., Shibata, A., Inoue, S., Kitayoshi, M., Okimoto, S., Fukushima, N., & Tsujiuchi, T. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.09.014 · Cited by 19
Resistance mechanisms of tumour cells to EGFR inhibitors
Morgillo, F., Cantile, F., Fasano, M., Troiani, T., Martinelli, E., & Ciardiello, F. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0354-6 · Cited by 19
“Regardless of their localisation within the KRAS gene, all these mutations impair the intrinsic GT-Pase activity of KRAS and prevent GAPs from promoting hydrolysis of GTP by RAS leading to constitutive, growth factor receptor-independent activation of KRAS signalling in tumour cells [ 17 ].”
BackgroundSchmidt, V. F., Wieland, I., Wohlgemuth, W. A., Ricke, J., Wildgruber, M., & Zenker, M. (2021) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62386 · Cited by 19
Snead, K., Wall, V. E., Ambrose, H., Esposito, D., & Drew, M. R. (2022) · Protein Expression and Purification · doi:10.1016/j.pep.2022.106061 · Cited by 19
Stem Cells in Brain Tumor Development
Llaguno, S. R. A., Chen, Y., McKay, R. M., & Parada, L. F. (2011) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-380916-2.00002-4 · Cited by 20
Bennani, B., Gilles, S., Fina, F., Nanni, I., Ibrahimi, S. A., Riffi, A. A., Nejjari, C., Benajeh, D.-A., Abkari, M. E., Martin, P., et al. (2010) · The International Journal of Biological Markers · doi:10.5301/jbm.2010.6091 · Cited by 18
Eum, K., Ahn, S. K., Kang, H., & Lee, M. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1446-0 · Cited by 18
Fang, Z., Marshall, C. B., Yin, J. C., Mazhab‐Jafari, M. T., Gasmi-Seabrook, G. M. C., Smith, M. J., Nishikawa, T., Xu, Y., Neel, B. G., & Ikura, M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.714196 · Cited by 21
“Resistance to the catalytic activity of GAPs is the major mechanism by which oncogenic RAS mutants maintain high activation levels in cells (39, 44), whereas germ-line RASopathy-associated RAS mutations are highly variable in their impact on GAP sensitivity, ranging from undetectable to profound impairment (31, 45).”
BackgroundRole of the HTLV-1 viral factors in the induction of apoptosis
Karimi, M. H., Mohammadi, H., Hemmatzadeh, M., Mohammadi, A., Rafatpanah, H., & Baradaran, B. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.034 · Cited by 19
KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma
Choi, S. M., Andea, A. A., Wang, M., Behdad, A., Shao, L., Zhang, Y., Lu, X., Dittmann, D., Castro, J., Chen, Y.-H., et al. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0758-0 · Cited by 21
Riecken, L. B., Tawamie, H., Dornblut, C., Buchert, R., Ismayel, A., Schulz, A., Schumacher, J., Sticht, H., Pohl, K. J., Cui, Y., et al. (2014) · Human Mutation · doi:10.1002/humu.22737 · Cited by 19
Seok, S. H., Na, Y., Han, J., Kim, T., Jung, H. M., Lee, B., Emelyanov, A., Parinov, S., & Park, J. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01393.x · Cited by 20
Management of moyamoya syndrome in patients with Noonan syndrome
Gupta, M., Choudhri, O., Feroze, A. H., Do, H. M., Grant, G. A., & Steinberg, G. K. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.11.017 · Cited by 18
Lee, W. S., Baek, J., Lee, J. N., & Lee, W. K. (2011) · International Journal of Surgical Pathology · doi:10.1177/1066896911400411 · Cited by 18
Herreros‐Villanueva, M., Gomez-Manero, N., Múñiz, P., Girón, C. G., & del Corral, M. J. C. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0236-6 · Cited by 21
Castellano, E., Guerrero, C., Núñez, A., Rivas, J. D. L., & Santos, E. (2009) · Genome biology · doi:10.1186/gb-2009-10-11-r123 · Cited by 20
Laranjeira, A. C., Berger, S., Kohlbrenner, T., Greter, N. R., & Hajnal, A. (2024) · Nature Communications · doi:10.1038/s41467-024-52556-3 · Cited by 26
“The importance of RAS/MAPK signaling during oncogenic transformation is well documented, stimulating tumor cell proliferation, migration, and invasion 15,16 .”
Reynolds, G., Gazzin, A., Carli, D., Massuras, S., Cardaropoli, S., Luca, M., Defilippi, B., Tartaglia, M., Ferrero, G. B., & Mussa, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083515 · Cited by 24
“The RAS/MAPK signaling pathway plays a pivotal role in somatic tumor development [83]; however, oncological risk does not appear significantly elevated in older children and adults with NS compared to the general population [84].”
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer
Miao, R., Yu, J. B., & Kim, R. D. (2025) · Cancers · doi:10.3390/cancers17091512 · Cited by 20
“This leads to the persistent activation of downstream signaling pathways, even in the absence of upstream growth factor stimuli [25,26].”
Amanlou, M., Hashemi, S., Sharifi, A., Zareei, S., Mohamedi, G., & Biglar, M. (2020) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.288425 · Cited by 17
Kim, S. T., Park, K. H., Kim, J. S., Shin, S. W., & Kim, Y. H. (2013) · Cancer Research and Treatment · doi:10.4143/crt.2013.45.1.55 · Cited by 18
Centroid-Based Actionable 3D Subspace Clustering
Sim, K., Yap, G.-E., Hardoon, D. R., Gopalkrishnan, V., Cong, G., & Lukman, S. (2012) · IEEE Transactions on Knowledge and Data Engineering · doi:10.1109/tkde.2012.37 · Cited by 18
Calvisi, D. F., Evert, M., & Dombrowski, F. (2012) · Molecular Biology International · doi:10.1155/2012/849874 · Cited by 17
Aga, S. S., Chowdri, N. A., Syeed, N., Banday, M. Z., Shah, Z. A., & Siddiqi, M. A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-300 · Cited by 17
Vav2 protein overexpression marks and may predict the aggressive subtype of ductal carcinoma in situ
Jiang, Y., Prabakaran, I., Wan, F., Mitra, N., Furstenau, D. K., Hung, R. K., Cao, S., Zhang, P. J., Fraker, D. L., & Guvakova, M. A. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-22 · Cited by 17
The Bisphenol A analogue Bisphenol S binds to K‐Ras4B – implications for ‘ BPA ‐free’ plastics
Schöpel, M., Herrmann, C., Scherkenbeck, J., & Stoll, R. (2016) · FEBS Letters · doi:10.1002/1873-3468.12056 · Cited by 18
Andò, S., Malivindi, R., Catalano, S., Rizza, P., Barone, I., Panza, S., Rovito, D., Emprou, C., Bornert, J.-M., LAVERNY, G., et al. (2017) · Oncogene · doi:10.1038/onc.2017.252 · Cited by 18
Zhang, R., Aimudula, A., Dai, J., & Bao, Y. (2020) · Bioscience Reports · doi:10.1042/bsr20194143 · Cited by 19
RetractedLongeri, M., Russo, V., Strillacci, M. G., Perillo, A., Carisetti, M., Cozzi, M. C., Neola, B., & Roperto, S. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.630089 · Cited by 17
Mass spectrometric detection of KRAS protein mutations using molecular imprinting
Norman, R. L., Singh, R., Muskett, F. W., Parrott, E. L., Rufini, A., Langridge, J., Runau, F., Dennison, A. R., Shaw, J., Piletska, E. V., et al. (2021) · Nanoscale · doi:10.1039/d1nr03180e · Cited by 19
Receptor for Activated Protein C Kinase 1 (RACK1) Is Overexpressed in Papillary Thyroid Carcinoma
Myklebust, L. M., Akslen, L. A., Varhaug, J. E., & Lillehaug, J. R. (2011) · Thyroid · doi:10.1089/thy.2010.0186 · Cited by 17
Yamasaki, M., Yusuke, O. M. I., FUJII, N., Ozaki, A., Nakama, A., Sakakibara, Y., Suiko, M., & Nishiyama, K. (2009) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.90322 · Cited by 19
Role of the ERas gene in gastric cancer cells
LIU, Y., WANG, Z., Li, H., Wu, Z., WEI, F., & Wang, H. (2013) · Oncology Reports · doi:10.3892/or.2013.2417 · Cited by 17
Vertical Pathway Targeting in Cancer Therapy
Shahbazian, D., Sznol, J. A., & Kluger, H. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00001-4 · Cited by 18
Lv, J.-M., Chen, L., Gao, Y., Huang, H., Pan, X., Liu, X., Chen, M., Qu, F., Li, L., Wang, J., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161280 · Cited by 17
K‐RasV14I‐induced Noonan syndrome predisposes to tumour development in mice
Hernández‐Porras, I., Schuhmacher, A. J., Garcia‐Medina, R., Jiménez, B., Cañamero, M., de Martino, A., & Guerra, C. (2016) · The Journal of Pathology · doi:10.1002/path.4719 · Cited by 16
Tian, L., Zhao, L., Sze, K. M., Kam, C. S., Ming, V. S., Wang, X., Zhang, V. X., Ho, D. W., Cheung, T. T., Chan, L., et al. (2021) · Hepatology · doi:10.1002/hep.32236 · Cited by 15
KRAS insertion mutations are oncogenic and exhibit distinct functional properties
White, Y. N., Bagchi, A., Ziffle, J. V., Sheth, A. I., Bollag, G. E., Zhang, C., Carias, H., Dickens, D. S., Loh, M. L., Shannon, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10647 · Cited by 16
Self-citationCutting the Brakes on Ras—Cytoplasmic GAPs as Targets of Inactivation in Cancer
Bellazzo, A., & Collavin, L. (2020) · Cancers · doi:10.3390/cancers12103066 · Cited by 21
“Ras proteins (K-Ras, N-Ras, and H-Ras) are small monomeric GTPases that modulate cell fate by linking receptor activation to intracellular signaling, thereby controlling cell growth, survival, migration, and metabolism [1].”
BackgroundiRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells
Sieber, B., Lu, F., Stribbling, S. M., Grieve, A. G., Ryan, A. J., & Freeman, M. (2022) · Journal of Cell Science · doi:10.1242/jcs.259949 · Cited by 17
Wang, J., Yang, H., Shen, Y., Wang, S., Lin, D., Ma, L., Han, X., & Shi, Y. (2013) · Cancer Biomarkers · doi:10.3233/cbm-130334 · Cited by 18
The impact of the genetic background in the Noonan syndrome phenotype induced by K-RasV14I
Hernández-Porras, I., Jiménez-Catalán, B., Schuhmacher, A. J., & Guerra, C. E. (2015) · Rare Diseases · doi:10.1080/21675511.2015.1045169 · Cited by 16
Onozato, W., Yamashita, K., Yamashita, K., Kuba, T., Katoh, H., Nakamura, T., Sato, T., Ihara, A., Okayasu, I., & Watanabe, M. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21710 · Cited by 18
Consequences of feedback in signal transduction for targeted therapies
Klinger, B., & Blüthgen, N. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140130 · Cited by 17
N-myristoyltransferase in the leukocytic development processes
Kumar, S., Singh, B., Dimmock, J. R., & Sharma, R. K. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1202-x · Cited by 17
“Myristoylation has also been linked to several other pathogenic states such as Noonan-like syndrome, which is a rare developmental disorder (Mazzanti et al. 2003; Schubbert et al. 2007; Cordeddu et al. 2009), diabetes (King et al.”
BackgroundKawabata, N., & Matsuda, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167940 · Cited by 18
Pre-Testicular, Testicular, and Post-Testicular Causes of Male Infertility
Dimitriadis, F., Adonakis, G. L., Kaponis, A. I., Mamoulakis, C., Takenaka, A., & Sofikitis, N. (2017) · Endocrinology · doi:10.1007/978-3-319-29456-8_33-1 · Cited by 16
Riffo‐Campos, Á. L., Gimeno-Valiente, F., Rodríguez, F. M., Cervantes, A. M. R., López‐Rodas, G., Franco, L., & Castillo, J. (2018) · Oncotarget · doi:10.18632/oncotarget.25016 · Cited by 18
Ksionda, O., Mues, M., Wandler, A. M., Donker, L., Tenhagen, M., Jun, J. E., Ducker, G. S., Matlawska‐Wasowska, K., Shannon, K., Shokat, K. M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193849 · Cited by 16
Self-citationRas-Superfamily GTP-ases in Ovarian Cancer
Cheng, K. W., Agarwal, R., & Mills, G. B. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-98094-2_11 · Cited by 16
A novel platform for mutation detection in colorectal cancer using a PNA-LNA molecular switch
Islam, M. S., Aktar, S., Moetamedirad, N., Xie, N., Lu, C., Gopalan, V., Lam, A. K.-Y., & Shiddiky, M. J. A. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116813 · Cited by 15
Zhu, J., Cao, X., Chen, Z., Lai, B., Xi, L., Zhang, J., Zhu, S., Qi, S., Liang, Y., Cao, F., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07061-2 · Cited by 17
Advancements in gene therapies targeting mutant KRAS in cancers
Wang, Y., Bui, T. A., Yang, X., Hutvágner, G., & Deng, W. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10243-9 · Cited by 23
Amissah, F., Duverna, R., Aguilar, B. J., Poku, R. A., Kiros, G.-E., & Lamango, N. S. (2014) · Europe PMC (PubMed Central) · Cited by 17
Aga, S. S. (2013) · Tumor Biology · doi:10.1007/s13277-013-0692-4 · Cited by 15
Cantariño, N., Fernández‐Figueras, M. T., Valero, V., Musulén, E., Malinverni, R., Granada, I., Goldie, S. J., Martín‐Caballero, J., Douet, J., Forcales, S. V., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30139 · Cited by 15
Standard chemotherapy with cetuximab for treatment of colorectal cancer
Li, X.-X., Liang, L., Huang, L.-Y., & Cai, S.-J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.7022 · Cited by 20
Okamoto, H., Matsukawa, T., Doi, S., Tsunoda, T., Sawata, Y., Naemura, M., Ohnuki, K., Shirasawa, S., & Kotake, Y. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3191-x · Cited by 15
Shao, J., Glorieux, C., Liao, J., Chen, P., Lu, W., Liang, Z., Wen, S., Hu, Y., & Huang, P. (2018) · Free Radical Research · doi:10.1080/10715762.2018.1462494 · Cited by 17
WDR76 mediates obesity and hepatic steatosis via HRas destabilization
Park, J., Jeong, W.-J., Seo, S. H., & Choi, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-56211-6 · Cited by 16
Ciblage de la voie de signalisation RAS pour le traitement des cancers
Mansi, L., Viel, E., Curtit, E., Médioni, J., & Tourneau, C. L. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2011.1380 · Cited by 21
Progressing from Gene Mutations to Cancer
Fearon, E. R., & Bommer, G. T. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50017-8 · Cited by 15
Kim, H., Kim, M., Lee, J.-H., Yu, H., & Hah, J. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.042 · Cited by 15
Kushiro, K., Yaginuma, T., Ryo, A., & Takai, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-03779-6 · Cited by 15
Kokkorakis, N., & Gaitanou, M. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i12.1553 · Cited by 17
Tuladhar, R., & Lum, L. (2015) · Biochemical Society Transactions · doi:10.1042/bst20140282 · Cited by 14
Pallegar, N. K., Ayre, D. C., & Christian, S. L. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00047 · Cited by 15
Huang, Y., Ren, G., Xu, C., Dong, S.-F., Wang, Y., Gan, Y., Zhu, L. X., & Feng, T.-Y. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-479 · Cited by 14
Role of PTPN11 (SHP2) in Cancer
Chan, G., & Neel, B. G. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3649-6_4 · Cited by 14
Wen, Z. H., Yun, G., Hebert, A. S., Kong, G., Ranheim, E. A., Finn, R., Rajagoplan, A., Li, S., Zhou, Y., Yu, M., et al. (2021) · Blood · doi:10.1182/blood.2020009082 · Cited by 14
Age-Dependent Prognostic Value of KRAS Mutation in Metastatic Colorectal Cancer
Özer, M., Goksu, S. Y., Sanford, N. N., Ahn, C. W., Beg, M. S., & Kazmi, S. M. A. (2021) · Future Oncology · doi:10.2217/fon-2021-0650 · Cited by 17
Possible etiological association of ovine papillomaviruses with bladder tumors in cattle
Falco, F. D., Cuccaro, B., TULLIO, R. D., Alberti, A., Cutarelli, A., Carlo, E. D., & Roperto, S. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199084 · Cited by 14
“Accordingly, the active GTP-bound conformation (Ras-GTP) accumulates in cells, thereby causing abnormal cell proliferation and differentiation (Schubbert et al., 2007).”
BackgroundRags connect mTOR and autophagy
Narita, M., & Inoki, K. (2012) · Small GTPases · doi:10.4161/sgtp.19422 · Cited by 15
Sharma, N., Sonavane, U., & Joshi, R. (2014) · European Biophysics Journal · doi:10.1007/s00249-014-0942-4 · Cited by 15
Inhibition of tumor growth by U0126 is associated with induction of interferon‐γ production
Ma, X., Wang, Q., Liu, Y., Chen, Y., Zhang, L., Jiang, M., Li, X., Xiang, R., Miao, Q., Duan, Y., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29038 · Cited by 15
Hotspot oncomutations: implications for personalized cancer treatment
Myers, M. B., Wang, Y., McKim, K. L., & Parsons, B. L. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.51 · Cited by 15
Molecularly Targeted Therapy in Acute Myeloid Leukemia
Gill, H., Leung, A. Y., & Kwong, Y. (2016) · Future Oncology · doi:10.2217/fon.15.314 · Cited by 15
Multiple giant cell lesions in a patient with Noonan syndrome with multiple lentigines
van den Berg, H., Schreuder, W. H., Jongmans, M. C. J., van Bommel-Slee, D., Witsenburg, B., & de Lange, J. (2016) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2016.05.013 · Cited by 16
Synthesis of novel Ral inhibitors: An in vitro and in vivo study
Yan, C., Theodorescu, D., Miller, B., Kumar, A., Kumar, V. V., Ross, D., & Wempe, M. F. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.021 · Cited by 15
Riffo‐Campos, Á. L., Castillo, J., Vallet-Sánchez, A., Ayala, G., Cervantes, A. M. R., López‐Rodas, G., & Franco, L. (2016) · Oncology Reports · doi:10.3892/or.2016.5210 · Cited by 16
How Genetics Has Helped Piece Together the MAPK Signaling Pathway
Ashton‐Beaucage, D., & Therrien, M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6424-6_1 · Cited by 19
Expanding the Genetic Spectrum of Noonan Syndrome
Noordam, C. (2007) · Hormone Research in Paediatrics · doi:10.1159/000110468 · Cited by 15
Lee, Y., Raisuddin, S., Rhee, J., Ki, J., Kim, I., & Lee, J. (2007) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2007.11.006 · Cited by 14
“It has also been suggested that specific ras proteins are processed differently and therefore follow distinct trafficking pathways (Mor and Philips, 2006; Schubbert et al., 2007).”
BackgroundInterleukin-1 signaling in solid organ malignancies
Dosch, A. R., Singh, S. P., Nagathihalli, N. S., Datta, J., & Merchant, N. B. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188670 · Cited by 15
Doghish, A. S., Zaki, M. B., Eldeib, M. G., Radwan, A., Moussa, R., Abdelwahab, M. M., Kizilaslan, E. Z., Alhamshry, N. A. A., Ashour, A. E., & Elimam, H. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.155044 · Cited by 15
Ghazali, N., Garassino, M. C., Leighl, N. B., & Bestvina, C. M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251323985 · Cited by 19
“It functions as a GTP/GDP exchange factor to promote conversion from RAL GDP to RAL GTP. 10,11 The downstream factors from RAL proteins include Rac/cell division cycle 42 (CDC42) for cell migration, TANK-binding kinase 1 associated with viral immunity, and phospholipase D involved with endocytosis 10,11 (Figure 1).”
Kim, R.-K., Suh, Y., Lim, E.-J., Yoo, K.-C., Lee, G.-H., Cui, Y., Son, A.-R., Hwang, E., Uddin, N., Yi, J.-M., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.023 · Cited by 13
KRAS Testing and Its Importance in Colorectal Cancer
Patil, D. T., Fraser, C. R., & Plesec, T. P. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0099-y · Cited by 14
“Activating KRAS mutations result in a permanently active GTP-bound form due to inhibition of the GTPase activity or insensitivity to GAPs [15].”
BackgroundWen, L., & Xie, M. (2014) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2013.12.024 · Cited by 13
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.